What TMA Precision Health does

TMA Precision Health, operating commercially under the brand Sunstone Health, is a Boston-based private health technology company founded in 2019 that markets an AI-driven platform to analyze employer health-plan claims data and identify members with undiagnosed or misdiagnosed rare and genetic conditions such as autism, epilepsy, and biotinidase deficiency. The platform combines whole genome sequencing with claims-data analysis and routes identified members into evidence-based testing and precision-medicine care teams, with four stated AI capabilities: anomaly detection across claims streams, predictive analytics for high-cost member risk stratification, knowledge retrieval to connect members with appropriate diagnostics, and process automation across the diagnosis-to-billing workflow. The company claims an average 60% cost reduction per case and cites an annual cost example of $51,403 for an individual misdiagnosed patient, though these are illustrative outcomes rather than independently validated results.

TMA's commercial model is an outcome-based flat fee per case, billed only after a confirmed diagnosis and care plan are delivered, with no PEPM charges or upfront fees — a structure designed to minimize adoption friction for self-funded employers. Distribution combines direct enterprise field sales to self-funded employers and health plans, a self-serve D2C consumer channel via the Sunstone Health web/app, and a broker/consultant channel, supported by thought-leadership content including the Sunstone Health Podcast launched in October 2025. Primary customer segments are self-funded employers and health plans, with secondary segments in individual patients and benefits brokers/consultants.

The operating team consists of five core members led by cofounder and CEO Joshua Resnikoff (a former biomedical engineer at the Wyss Institute at Harvard Medical School), plus an eight-member advisory bench including senior MassGeneral Brigham clinicians and executives from Illumina, Medco, Proteus, and Epstein Health. The only disclosed funding event is a $20,000 investment from Lighthouse Labs RVA in August 2022. HIPAA and GDPR compliance are indicated on the homepage, but no CLIA certification, FDA pathway, patents, or peer-reviewed AI validation are disclosed.

Name

TMA Precision Health

Legal name

TMA Precision Health

Website

https://tmaprecisionhealth.com

Company type

Private

Founded year

2019

Headcount range

11–50 employees

Short description

TMA Precision Health (Sunstone Health) is a Boston-based health technology company that uses AI to analyze employer health-plan claims data and identify undiagnosed rare and genetic conditions, selling outcome-based diagnostic and care-coordination services to self-funded employers, health plans, brokers, and individual patients.

Ownership category

akta.pro rank

Product category

Healthcare AI / Precision Diagnostics Software

NAICS

Medical and Diagnostic Laboratories (62151), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Health and Welfare Funds (525120)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Diagnostic & Triage Decision Support (HLACAGAA), De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK)

Keywords

• Precision health diagnostics
• AI claims analysis
• Genomic risk detection
• Rare disease identification
• Employer health benefits

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Outcome-based flat fee per case: Revenue is generated via a flat fee charged per case/engagement, billed only after delivery of results. No PEPM (per employee per month) charges. Designed as outcome-based pricing where payment aligns with successful case completion.
2. Direct-to-consumer precision health services: Revenue from patients paying out of pocket for whole genome testing and AI-powered analysis services.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

TMA Precision Health (Sunstone Health) sells an AI-driven precision health platform that ingests employer health plan claims data to surface members with undiagnosed or misdiagnosed rare and genetic conditions such as autism, epilepsy, and biotinidase deficiency, then coordinates whole genome testing and precision care delivery. The service is sold to self-funded employers, health plans, and benefits brokers on an outcome-based flat-fee-per-case model, with a parallel direct-to-consumer channel for patients paying out of pocket.

Product overview

TMA Precision Health operates a single unified AI platform branded as Sunstone Health, built around three interlocking capabilities: (1) the AI Detection & Insights engine, which ingests employer claims data to surface undiagnosed or misdiagnosed rare and genetic conditions such as autism, epilepsy, and biotinidase deficiency; (2) Personalized Guidance, which routes identified members to advanced diagnostics like whole genome testing and expert precision care; and (3) Precision Care Coordination, which operationalizes onboarding, employer approval per case, and care team integration. The platform is delivered to employer-sponsored health plans under a Risk-Free Flat-Fee Pricing Model (no PEPM, no upfront fees, pay only per confirmed diagnosis) and is supported by a content/community layer via the Sunstone Health Podcast and on-site initiatives such as Epilepsy Awareness Day at Disneyland.

Differentiator

Problem solved

Functional benefit

Products and services

• Sunstone Health Platform AI-driven platform that analyzes employer health plan claims data to identify members with undiagnosed or misdiagnosed rare and genetic conditions such as autism and epilepsy, coordinates precision care with their providers, and bills a flat fee only after a confirmed diagnosis and care plan are delivered. Sold to self-funded employers, health plans, and benefits brokers.
• On-site Genomic Testing at Epilepsy Awareness Day at Disneyland 2025 On-site whole genome testing service delivered to families at the Epilepsy Awareness Day 2025 event at Disneyland, enabling diagnostic testing access in a community setting for the epilepsy community.
• Sunstone Health Podcast Original podcast hosted by CEO Josh Resnikoff covering rare disease journeys, healthcare innovation, and partnerships such as the Epilepsy Awareness Day at Disneyland collaboration with Brad Levy / Sophie's Journey.

Quantifiable outcome

• 60% average cost reduction per case
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Color Health: Population genomics platform offering genetic testing and precision health programs to employers and health plans. Most directly comparable to TMA on the employer-facing genomics + care coordination model.
• Fabric Genomics: AI-driven genomics interpretation platform used by hospitals and labs to identify rare disease variants. Comparable to TMA's AI-on-genomics approach applied to clinical diagnostic workflows.
• Carrum Health: Value-based care platform that helps self-funded employers reduce high-cost claims through centers of excellence and bundled care. Closely comparable outcome-based cost-reduction model aimed at self-funded employers.
• GeneDx: Rare-disease genetic diagnostics company with whole genome and exome sequencing capabilities. Closely comparable to TMA's rare-disease diagnostic focus and whole-genome testing offering.

Broad incumbents

• Arcadia: Healthcare claims and clinical data platform used by health plans and providers for population health and risk stratification. Comparable to TMA's claims-data analysis layer feeding AI-driven member identification.
• Collective Health: End-to-end health benefits platform for self-funded employers. Comparable to TMA's self-funded employer buyer and outcome-cost-reduction value proposition, though at significantly larger scale.
• Health Catalyst: Large healthcare data and analytics platform that ingests claims and clinical data for population health and cost reduction. Comparable to TMA's claims-data AI engine, but at much broader enterprise scale.
• 23andMe: Consumer-facing genetics company that also offers health-risk and carrier screening reports. Comparable to TMA's D2C whole-genome component and consumer health-risk positioning, with substantially larger consumer brand.
• Invitae: Established genetic testing company with broad rare-disease, hereditary cancer, and reproductive health offerings. Comparable to TMA's whole-genome rare-disease focus, though Invitae is far larger and more diversified.

Emerging players

• Mendel: AI company that structures and reasons over medical records and clinical text to surface patient cohorts and trial candidates. Comparable to TMA's AI-on-healthcare-data approach, although Mendel's focus is clinical research rather than employer benefits.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TMA Precision Health